Compare PRAX & CAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | CAG |
|---|---|---|
| Founded | 2015 | 1919 |
| Country | United States | United States |
| Employees | N/A | 26100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.4B |
| IPO Year | 2020 | 1994 |
| Metric | PRAX | CAG |
|---|---|---|
| Price | $282.31 | $13.20 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 17 |
| Target Price | ★ $572.13 | $16.88 |
| AVG Volume (30 Days) | 475.2K | ★ 14.4M |
| Earning Date | 05-08-2026 | 04-01-2026 |
| Dividend Yield | N/A | ★ 9.84% |
| EPS Growth | N/A | ★ 233.33 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,500,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7,758.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.25 | $12.53 |
| 52 Week High | $366.52 | $21.78 |
| Indicator | PRAX | CAG |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 43.64 |
| Support Level | $238.77 | $12.53 |
| Resistance Level | $342.62 | $14.56 |
| Average True Range (ATR) | 21.47 | 0.42 |
| MACD | 0.62 | 0.07 |
| Stochastic Oscillator | 39.34 | 43.93 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Conagra Brands is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). Most of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, and Wish-Bone. The company primarily sells through the US retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.